OGN - Organon Q1 2023 earnings on deck what to expect

2023-05-03 14:25:08 ET

• Organon ( NYSE: OGN ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open.
• The consensus EPS estimate is $1.16 and the consensus revenue estimate is $1.54B.
• Over the last 1 year, OGN has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time.
• Over the last 3 months, EPS estimates have seen 1 upward revision and 4 downward. Revenue estimates have seen 3 upward revisions and 1 downward.
• The company on Feb. 16 reported Q4 Non-GAAP EPS of $0.81, missing estimates by $0.10. Revenue of $1.49B was -6.9% Y/Y and missed consensus by $10M.
• OGN has a Quant rating of "Hold", with a 2.69 rating score.
• OGN has an industry ranking of 122 out of 221 among healthcare stocks, as per SA's Quant ranking.
• Wall Street analysts and Seeking Alpha authors rate the OGN stock "Buy".
• Recent Analysis: The Value Investor, leader of the " Value In Corporate Events " Investing Group on Seeking Alpha, wrote in a recently published report , "Organon has seen mostly margin disappointments since the spinoff from Merck. While the performance is not comforting, valuations are non-demanding. Leverage is high, but stabilization in the business, longer-term maturities, and fixed rates alleviate many leverage concerns."
• In mid-March, Raymond James launched its coverage on Organon with an "Outperform" recommendation citing its potential in the biosimilar space with the upcoming launch of Hadlima, a copycat version of AbbVie's blockbuster arthritis therapy Humira.
• Other analysis from our contributors: Don't Buy Viatris And Organon Just Because Of The Dividends by Deep Value Ideas.
• Organon: Too Cheap To Ignore by Gen Alpha, member of the " Hoya Capital Income Builder " Investing Group on Seeking Alpha.
• OGN stock fell 7% in 2022, while the benchmark S&P 500 index slipped nearly 20% for the year.
• Stock is down 13% so far this year as of Tuesday's close.

For further details see: